A detailed history of Jacobs Levy Equity Management, Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 566,328 shares of MGNX stock, worth $2.16 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
566,328
Previous 418,890 35.2%
Holding current value
$2.16 Million
Previous $1.78 Million 4.66%
% of portfolio
0.01%
Previous 0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.0 - $5.55 $442,314 - $818,280
147,438 Added 35.2%
566,328 $1.86 Million
Q2 2024

Aug 14, 2024

BUY
$3.31 - $18.51 $896,586 - $5.01 Million
270,872 Added 183.0%
418,890 $1.78 Million
Q1 2024

May 15, 2024

BUY
$9.77 - $21.47 $322,791 - $709,347
33,039 Added 28.73%
148,018 $2.18 Million
Q4 2023

Feb 14, 2024

SELL
$4.48 - $10.11 $1.27 Million - $2.88 Million
-284,505 Reduced 71.22%
114,979 $1.11 Million
Q3 2023

Nov 16, 2023

SELL
$4.48 - $6.19 $24,648 - $34,057
-5,502 Reduced 1.36%
399,484 $1.86 Million
Q2 2023

Aug 14, 2023

BUY
$4.62 - $7.54 $465,991 - $760,514
100,864 Added 33.17%
404,986 $2.17 Million
Q1 2023

May 15, 2023

BUY
$4.82 - $7.24 $1.2 Million - $1.8 Million
248,386 Added 445.65%
304,122 $2.18 Million
Q4 2022

Feb 14, 2023

BUY
$3.34 - $6.98 $186,158 - $389,037
55,736 New
55,736 $373,000
Q2 2022

Aug 15, 2022

SELL
$2.25 - $9.99 $218,250 - $969,030
-97,000 Reduced 57.66%
71,224 $210,000
Q1 2022

May 16, 2022

BUY
$8.12 - $16.9 $1.37 Million - $2.84 Million
168,224 New
168,224 $1.48 Million
Q4 2020

Feb 16, 2021

SELL
$19.41 - $26.0 $358,774 - $480,584
-18,484 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$24.69 - $31.6 $4.74 Million - $6.07 Million
-192,152 Reduced 91.22%
18,484 $466,000
Q2 2020

Aug 17, 2020

SELL
$5.2 - $29.12 $61,406 - $343,878
-11,809 Reduced 5.31%
210,636 $5.88 Million
Q1 2020

May 15, 2020

BUY
$4.28 - $12.11 $952,064 - $2.69 Million
222,445 New
222,445 $1.3 Million
Q2 2019

Aug 13, 2019

SELL
$14.51 - $19.71 $497,693 - $676,053
-34,300 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$11.11 - $25.6 $1.21 Million - $2.78 Million
-108,566 Reduced 75.99%
34,300 $617,000
Q4 2018

Feb 14, 2019

BUY
$11.75 - $21.42 $58,750 - $107,100
5,000 Added 3.63%
142,866 $1.81 Million
Q3 2018

Nov 14, 2018

SELL
$19.26 - $23.46 $217,715 - $265,191
-11,304 Reduced 7.58%
137,866 $2.96 Million
Q2 2018

Aug 14, 2018

BUY
$19.78 - $24.67 $559,239 - $697,494
28,273 Added 23.39%
149,170 $3.08 Million
Q1 2018

May 15, 2018

SELL
$18.89 - $32.46 $512,655 - $880,931
-27,139 Reduced 18.33%
120,897 $3.04 Million
Q4 2017

Feb 13, 2018

BUY
$16.19 - $20.3 $1.21 Million - $1.51 Million
74,485 Added 101.27%
148,036 $2.81 Million
Q3 2017

Nov 14, 2017

BUY
$15.52 - $18.94 $840,578 - $1.03 Million
54,161 Added 279.32%
73,551 $1.36 Million
Q2 2017

Nov 09, 2017

BUY
N/A
19,390
19,390 $340,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $234M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.